Avalo Therapeutics, Inc.

NASDAQ:AVTX

Biotechnology

Healthcare
$6.70 -2.18%

-$0.34 today

Market cap
$387.41M
Beta
0.82
P/E (TTM)
-3.6
EPS (TTM)
-$4.21
52W Low $4.50High $24.27

Volume 1.58M

Average 1.61M

Returns on capital

Avalo Therapeutics, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-94.2%

avg -823.4%

ROIC

-70.2%

avg -111.0%

ROA

-67.2%

avg -93.1%

Analysis

ROA is currently the strongest return metric at -67.2% versus its period average of -93.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Garry A. Neil

President, Chief Executive Officer & DirectorUSD 1.08M72——

Mittie Doyle FACR

Chief Medical OfficerUSD 750.13K61——

Christopher Ryan Sullivan

Chief Financial Officer & Head of Investor relationsUSD 629.4K4239.90K0.35%

Taylor Boyd

Chief Business OfficerUSD 519.02K3795.00K0.84%

Barbara S. Slusher

Founder and Member of Scientific Advisory Board—61——

Dino C. Miano

Senior Vice President of CMC & Technical Operations————

Solomon H. Snyder

Founder and Chairman of Scientific Advisory Board—87——

Paul C. Varki

Chief Legal Officer—53——

Jennifer Riley

Chief Strategy Officer—5137.04K0.33%

Ashley Ivanowicz

Senior Vice President of Human Resources————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Sep 16, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

0

$0.00

Sells

41

$8.34M

Net Transaction Value

−$8.34M

Net selling

Most Active

Sullivan Christopher Ryan

17 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Sep 16, 26

Sullivan Christopher Ryan

Direct

Sell$202.4K
Sep 10, 26

Sullivan Christopher Ryan

Direct

Sell$179.5K
Aug 28, 26

Doyle Mittie

Direct

Sell$13.6K
Aug 18, 26

Sullivan Christopher Ryan

Direct

Sell$622.3K
Aug 17, 26

Sullivan Christopher Ryan

Direct

Sell$753.3K
Aug 17, 26

Sullivan Christopher Ryan

Direct

Sell$74.8K
Aug 17, 26

Doyle Mittie

Direct

Sell$20K
Aug 11, 26

Riley Jennifer

Direct

Sell$52K
Aug 10, 26

Doyle Mittie

Direct

Sell$13.6K
Jul 27, 26

Doyle Mittie

Direct

Sell$20K

1–10 of 41

Summary

Insiders reported 0 buys worth $0.00 and 41 sells worth $8.34M over the last 12 months. That adds up to net selling of $8.34M. Sullivan Christopher Ryan was the most active insider with 17 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A2 analysts
RevenueN/AN/A-85.2%
+344.3% (5yr)3 analysts
Net IncomeN/AN/AN/A
N/A3 analysts
EBITN/AN/AN/A
N/A3 analysts

Analysis

Recent growth has been strongest in Revenue at -85.2% over three years. Forward estimates point to Revenue at +344.3% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does Avalo Therapeutics, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about AVTX's management, answered from reported figures.

Who manages AVTX?

Avalo Therapeutics, Inc. (AVTX) lists 10 active executives. The top listed executive is Barbara S. Slusher, Founder and Member of Scientific Advisory Board.

Are AVTX insiders buying or selling?

Recent insider activity shows net buying of $21.18M.